1. *MLL*-rearranged acute lymphoblastic leukemia cells display unique and ample deregulated gene expression profiles that differ from those profiles found in other types of acute lymphoblastic leukemia specific ALL subtypes. (this thesis)

2. Congenital acute lymphoblastic leukemia is not invariably fatal and treatment with curative intent is justified. (this thesis)

3. The level of *MEIS1* expression is a strong predictor of outcome in wild-type *MLL* infant acute lymphoblastic leukemia, which may direct novel treatment strategies for wild-type *MLL* infant acute lymphoblastic leukemia. (this thesis)

4. Knock-down of the *MLL* fusion genes provides a rich source of potential targets for therapeutic intervention in *MLL*-rearranged leukemias. (this thesis)

5. *CDK6* is a direct target of *MLL* fusion proteins and plays an important role in the proliferative advantage of *MLL*-rearranged acute lymphoblastic leukemia cells. (this thesis)

6. Global gene-expression profiling has the potential to reveal new dimensions of the pathologic features of acute lymphoblastic leukemia and to identify novel therapeutic targets. (CH Pui, NEJM, 2006)

7. The *MLL* fusion alone may be sufficient to spawn an aggressive leukemia in infants. (Armstrong, Cancer Cell, 2015)

8. Combining targeted therapies may allow dose reduction of individual agents, thereby minimizing toxicities, while maintaining therapeutic efficacy. (Placke, Blood, 2014)

9. It’s far more important to know what person the disease has than what disease the person has. (Hippocrates)

10. Clinical effects of homeopathy are placebo effects. (Shang, Lancet, 2005)

11. The best argument against democracy is a five-minute conversation with the average voter. (Winston Churchill)

Marieke van der Linden

Rotterdam, december 2015